Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIIB059 in Healthy Volunteers and SLE
NCT02106897Phase 1Completed
- Sponsor
- Biogen
- Start
- Apr 2014
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of litifilimab in systemic lupus erythematosus (SLE) (19 cohorts), sponsored by Biogen. Primary endpoint: Adverse Events and Serious Adverse Events. Started Apr 2014; status: completed.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02106897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106897.